Affimed NV
AFMD0.130USD
-0.004-2.99%
Handelsschluss 05/14, 16:00（ET）Kurse um 15 Minuten verzögert
2.13MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Affimed NV Unternehmen
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Unternehmensinformationen
Unternehmens-codeAFMD
Name des UnternehmensAffimed NV
IPO-datumSep 12, 2014
Gegründet am2014
CEOMr. Shawn M. Leland
Anzahl der mitarbeiter76
WertpapierartOrdinary Share
GeschäftsjahresendeSep 12
AddresseIm Neuenheimer Feld 582
StadtHEIDELBERG
BörseNASDAQ Global Market Consolidated
LandGermany
Postleitzahl69120
Telefon49621560030
Websitehttps://www.affimed.com/
Unternehmens-codeAFMD
IPO-datumSep 12, 2014
Gegründet am2014
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Ms. Uta Kemmerich-Keil
Ms. Uta Kemmerich-Keil
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
11.00K
+83.33%
Mr. Shawn M. Leland
Mr. Shawn M. Leland
Chief Executive Officer, Member of the Management Board
Chief Executive Officer, Member of the Management Board
--
--
Dr. Bernhard R. M. Ehmer
Dr. Bernhard R. M. Ehmer
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Thomas Hecht, M.D.
Dr. Thomas Hecht, M.D.
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Wolfgang Fischer, Ph.D.
Dr. Wolfgang Fischer, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
145.54K
+34.45%
Ms. Denise Mueller
Ms. Denise Mueller
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
Chief Business Officer and Co-President Affimed Inc, Member of the Management Board
89.88K
+65.92%
Dr. Andreas Harstrick, M.D.
Dr. Andreas Harstrick, M.D.
Chief Medical Officer, Member of the Management Board
Chief Medical Officer, Member of the Management Board
76.04K
+88.54%
Dr. Mathieu Simon
Dr. Mathieu Simon
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
15.00K
+36.36%
Mr. Harry Welten
Mr. Harry Welten
Consulting Chief Financial Officer, Member of the Management Board
Consulting Chief Financial Officer, Member of the Management Board
15.00K
+36.36%
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
14.00K
+16.67%
Umsatzaufteilung
Währung: EURUpdate-Zeit: Sun, Apr 6
Währung: EURUpdate-Zeit: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
Nach RegionEUR
Name
Umsatz
Anteil
United States
155.00K
100.00%
Germany
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Collaboration revenue
155.00K
0.00%
Service revenue
0.00
0.00%
Aktionäre
Update-Zeit: 22 hours ago
Update-Zeit: 22 hours ago
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Aktionärsstatistik
Aktionäre
Anteil
Gilde Healthcare Partners B.V.
5.34%
683 Capital Management LLC
4.30%
New Enterprise Associates (NEA)
2.91%
Point72 Asset Management, L.P.
2.25%
Hoess (Adi Ph.D.)
2.10%
Other
83.11%
Art
Aktionäre
Anteil
Hedge Fund
8.99%
Venture Capital
8.49%
Individual Investor
6.01%
Investment Advisor/Hedge Fund
2.72%
Investment Advisor
1.62%
Research Firm
0.83%
Other
71.34%
Institutionelle Beteiligung
Update-Zeit: Sat, Feb 22
Update-Zeit: Sat, Feb 22
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
194
4.37M
28.73%
-2.85M
2024Q4
223
4.37M
28.70%
-3.86M
2024Q3
244
6.36M
129.59%
-2.88M
2024Q2
256
6.34M
129.44%
-2.70M
2024Q1
265
6.05M
127.57%
-3.49M
2023Q4
282
6.20M
128.84%
-3.49M
2023Q3
294
6.99M
46.94%
-2.84M
2023Q2
315
7.55M
50.71%
-3.53M
2023Q1
317
8.81M
59.15%
-2.41M
2022Q4
311
9.75M
66.09%
-701.23K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Gilde Healthcare Partners B.V.
812.50K
5.34%
+812.50K
--
Mar 15, 2024
683 Capital Management LLC
654.60K
4.3%
-270.00K
-29.20%
Dec 31, 2024
New Enterprise Associates (NEA)
442.65K
2.91%
--
--
Dec 31, 2024
Point72 Asset Management, L.P.
342.86K
2.25%
--
--
Dec 31, 2024
Hoess (Adi Ph.D.)
319.68K
2.1%
+66.08K
+26.06%
Mar 15, 2024
Tang Capital Management, LLC
148.31K
0.97%
--
--
Dec 31, 2024
Fischer (Wolfgang)
145.54K
0.96%
+37.29K
+34.45%
Mar 15, 2024
The Vanguard Group, Inc.
129.56K
0.85%
--
--
Dec 31, 2024
Intellectus Partners, LLC
126.41K
0.83%
+32.05K
+33.97%
Dec 31, 2024
Citadel Advisors LLC
114.77K
0.75%
+107.96K
+1.58K%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Tue, May 6
Update-Zeit: Tue, May 6
Name
Anteil
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco Nasdaq Biotechnology ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
iShares Biotechnology ETF
0%
Fidelity Enhanced Small Cap ETF
Anteil0%
SPDR S&P International Small Cap ETF
Anteil0%
ProShares Ultra Nasdaq Biotechnology
Anteil0%
Invesco Nasdaq Biotechnology ETF
Anteil0%
SPDR Portfolio Developed World ex-US ETF
Anteil0%
iShares Biotechnology ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Datum
Art
Verhältnis
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1
Mar 06, 2024
Merger
10<1